BR112021009392A8 - Compostos, composições e métodos para o tratamento de sepsia - Google Patents

Compostos, composições e métodos para o tratamento de sepsia

Info

Publication number
BR112021009392A8
BR112021009392A8 BR112021009392A BR112021009392A BR112021009392A8 BR 112021009392 A8 BR112021009392 A8 BR 112021009392A8 BR 112021009392 A BR112021009392 A BR 112021009392A BR 112021009392 A BR112021009392 A BR 112021009392A BR 112021009392 A8 BR112021009392 A8 BR 112021009392A8
Authority
BR
Brazil
Prior art keywords
treatment
compositions
sepsis
methods
compounds
Prior art date
Application number
BR112021009392A
Other languages
English (en)
Other versions
BR112021009392A2 (pt
Inventor
Louise Søberg Kjølbye Anne
C Angus Derek
James Russell
Agerlin Windeløv Nis
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR112021009392A2 publication Critical patent/BR112021009392A2/pt
Publication of BR112021009392A8 publication Critical patent/BR112021009392A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

compostos, composições e métodos para o tratamento de sepsia. são reveladas aqui composições compreendendo selepressina para uso no tratamento de sepsia em um paciente. a composição compreendendo selepressina pode ser administrada em um período de seis horas desde o momento em que o paciente requer terapia com vasopressores. os pacientes podem ter uma concentração de lactato no soro menor do que cerca de 2 mmol/l antes do tratamento e/ou uma razão entre pressão parcial de oxigênio no sangue arterial e fração de oxigênio inspirado (pao2/fio2) maior do que cerca de 200 antes do tratamento. também são revelados métodos relacionados.
BR112021009392A 2018-11-15 2019-11-14 Compostos, composições e métodos para o tratamento de sepsia BR112021009392A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767889P 2018-11-15 2018-11-15
US62/767,889 2018-11-15
PCT/IB2019/059788 WO2020100080A1 (en) 2018-11-15 2019-11-14 Compounds, compositions and methods for treating sepsis

Publications (2)

Publication Number Publication Date
BR112021009392A2 BR112021009392A2 (pt) 2021-08-10
BR112021009392A8 true BR112021009392A8 (pt) 2022-04-19

Family

ID=68655588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009392A BR112021009392A8 (pt) 2018-11-15 2019-11-14 Compostos, composições e métodos para o tratamento de sepsia

Country Status (10)

Country Link
US (1) US20220008499A1 (pt)
EP (1) EP3880226A1 (pt)
JP (1) JP2022507380A (pt)
KR (1) KR20210093925A (pt)
CN (1) CN113164550A (pt)
AU (1) AU2019381328A1 (pt)
BR (1) BR112021009392A8 (pt)
CA (1) CA3119792A1 (pt)
MX (1) MX2021005693A (pt)
WO (1) WO2020100080A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
JO2937B1 (en) 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
ES2566143T3 (es) * 2006-02-13 2016-04-11 Ferring B.V. Uso de agonistas peptídicos de receptor de vasopresina
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
RU2673455C2 (ru) * 2013-03-20 2018-11-27 Сфинготек Гмбх Адреномедуллин для направленной терапии по снижению кровяного давления

Also Published As

Publication number Publication date
AU2019381328A1 (en) 2021-06-10
WO2020100080A1 (en) 2020-05-22
US20220008499A1 (en) 2022-01-13
CN113164550A (zh) 2021-07-23
EP3880226A1 (en) 2021-09-22
MX2021005693A (es) 2021-07-07
JP2022507380A (ja) 2022-01-18
BR112021009392A2 (pt) 2021-08-10
KR20210093925A (ko) 2021-07-28
CA3119792A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
Minamishima et al. Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3–dependent mechanism in mice
Burroughs et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding: emergency control and prevention of early variceal rebleeding
JP2023036871A (ja) 心不全の治療用組成物
DUKES Jr et al. Transaminase elevations in patients receiving bovine or porcine heparin
Lee Oxidative stress due to anesthesia and surgical trauma and comparison of the effects of propofol and thiopental in dogs
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
Martinez-Abundis et al. The obesity-related peptide leptin sensitizes cardiac mitochondria to calcium-induced permeability transition pore opening and apoptosis
BR112021024886A2 (pt) Métodos de tratar a doença de fabry em pacientes com insuficiência renal
WILSON et al. Some observations on 132 patients with septic shock
EA201290278A1 (ru) Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов
Bian et al. Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties
BR112021009392A8 (pt) Compostos, composições e métodos para o tratamento de sepsia
BRPI0416461A (pt) método para o tratamento de episódios de sangramento, formulação farmacêutica, e, uso de um polipeptìdeo fxi
Arslantas et al. Normal saline versus balanced crystalloid solutions for kidney transplantation
Kiralp et al. A novel treatment modality for myofascial pain syndrome: hyperbaric oxygen therapy
Landoni et al. Intravenous amino acid therapy for kidney protection in cardiac surgery a protocol for a multi-centre randomized blinded placebo controlled clinical trial. The PROTECTION trial
Niemann et al. Role of spleen and liver for enhanced hemostatic competence following administration of adrenaline to humans
Loftus et al. Clonidine restores vascular endothelial growth factor expression and improves tissue repair following severe trauma
Xing et al. Bradykinin contributes to sympathetic and pressor responses evoked by activation of skeletal muscle afferents P2X in heart failure
BRPI0612456A2 (pt) composiÇÕes e mÉtodos para o tratamento da malÁria com cupredoxina e citocromo
Stowell Effects of storage on the biology and clinical efficacy of the banked red blood cell
Spero et al. Treatment of amyloidosis associated factor X deficiency
EA201791319A1 (ru) Композиция хлорофиллов
Polito et al. Adrenocortical cell tolerance to lipopolysaccharide: a new mechanism for critical illness related corticosteroid insufficiency
Yurttas et al. POS1381 BIOLOGIC TREATMENT OF ADULT-ONSET STILL’S DISEASE: A SINGLE CENTER EXPERIENCE